- Quotient Sciences and CPI have signed a memorandum of understanding to establish a joint venture focused on accelerating RNA-based therapies.
- The initiative will integrate mRNA synthesis, LNP formulation, clinical manufacturing, and early-phase testing under one framework.
Quotient Sciences and UK technology innovation centre CPI have signed a memorandum of understanding (MoU) to create a joint venture (JV) aimed at accelerating the development of RNA-based therapies.
The partnership will combine Quotient Sciences’ Translational Pharmaceutics® platform with CPI’s expertise in small-scale RNA manufacture and lipid nanoparticle (LNP) encapsulation. Together, they will provide an integrated pathway for the development of mRNA drug products, addressing rising demand for agile solutions in this area.
According to Quotient Sciences CEO Thierry Van Nieuwenhove, the collaboration offers “a highly streamlined pathway to early-phase clinical trials for mRNA drug candidates,” with clinical batches moving from plasmid to clinical dose in as little as two months.
The JV framework will integrate mRNA synthesis, LNP formulation development, clinical manufacturing, and early-stage testing. This model is designed to shorten timelines and increase clinical success rates by allowing developers to adjust dose and formulation based on real-time data from early trials.
CPI CEO Frank Millar said the initiative reflects a joint commitment to support the RNA ecosystem and enable scalable, sustainable development pathways for mRNA therapies. The agreement also marks an extension of Translational Pharmaceutics, which has been applied to more than 500 small molecule and peptide programmes, into RNA-based modalities.
